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Abstract
Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that inhibits fibrinolysis by blocking the interaction
of plasminogen with the lysine residues of fibrin. Historically, TXA is commonly used for reduction of blood loss in
perioperative situations, while recently it has attracted attention for clinical use in the trauma field. In 2010, the Clinical
Randomization of an Antifibrinolytic in Significant Hemorrhage 2 (CRASH-2) trial demonstrated that intravenous
administration of TXA improved mortality significantly in trauma patients with significant bleeding. After the launch of its
sensational results, the main stream treatment protocol in trauma changed worldwide to include TXA administration.
In this review, first we summarize the recent evidence or recommendations in the related guidelines concerning TXA.
Also, we next tried to explore in detail not only the benefits but also the harm introduced by TXA in trauma patients,
because the main adverse event results for TXA, such as vascular occlusive events in the CRASH-2 trial, are still being
discussed in several papers. Thus, we briefly summarized the evidence for the safety of TXA administration by a
systematic review method using observational studies. Consequently, the pooled relative risk for venous
thromboembolisms was 1.61 (95% CI, 0.86–3.01), indicating a non-significant increase in the venous thromboembolism
risk of TXA therapy.
Regarding the basic mechanism, TXA potentially possesses the risk of venous thromboembolisms, so it should be used
cautiously and selectively. Further investigation is needed to delineate the optimal targeted trauma patients to earn
the maximum survival benefits with minimized risk of thrombotic complications.
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Background
As approximately 1,300,000 individuals die from se-
vere trauma, it is one of the leading causes of death
in the world [1]. Hemorrhaging plays an important
role in deaths from trauma; it accounts for 30 to
40% of trauma deaths and also increases the mortal-
ity of central nervous system injuries [2]. Further-
more, inadequate hemorrhage control in the initial
treatment is considered to be the leading cause of
potentially preventable deaths occurring after arrival
in hospitals [3].
Tranexamic acid (TXA) is a long-established antifibri-
nolytic drug that was developed in Japan in 1965 [4, 5].
Historically, it is commonly used for a reduction of
the blood loss in perioperative situations including
cardiac, orthopedic, oral, gynecological, and urological
surgeries [6–11]. Several meta-analyses elucidated the
efficacy of TXA on the blood transfusion require-
ments [12, 13]. In 2010, the results of the Clinical
Randomization of an Antifibrinolytic in Significant
Hemorrhage 2 (CRASH-2) trial, the first multicenter
randomized, placebo-controlled trial evaluating the
effects of TXA in patients with trauma, were pub-
lished in Lancet [14]. After the launch of its sensa-
tional results, the main stream treatment protocol in
trauma changed worldwide to include TXA adminis-
tration [15, 16]. However, unrestricted usage of TXA
has been criticized and reconsidered since several
studies have pointed out its potential detrimental
effects [17–19].
In this review, we will explore the benefits as well as
harm introduced by TXA in patients with trauma in
order to find out the best treatment option.
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Pathophysiology of trauma-induced coagulopathy
Hemorrhaging can lead to coagulopathy due to multiple
factors: shock, acidemia, hypothermia, and hemodilution
following resuscitation. A recent study has shown that a
hemostatic abnormality is identified in 25% of trauma
patients and is associated with increased mortality
[20, 21]. The coagulation system in the circulation is
activated immediately after trauma by an increased
tissue factor production, thrombin generation, and its
activation [22]. Simultaneously, tissue hypoxia and is-
chemia induced by hemorrhagic shock increases the
release of the tissue-plasminogen activator (t-PA)
from endothelial Weibel-Palade bodies and causes
fibrinolysis [23]. Those are the key pathogenesis of
the coagulo-fibrinopathy following trauma. In other
words, trauma-induced coagulopathy in the early
phase of trauma can be categorized into disseminated
intravascular coagulation (DIC) with a fibrinolytic
phenotype [24, 25]. It leads to systemic bleeding that
is not able to be dealt with by surgical procedures
and results in a high mortality and morbidity. These
findings suggest that treatment against hyperfibrinoly-
sis reduces the mortality of severe trauma with sig-
nificant hemorrhaging.
An elevation of the plasminogen activator inhibitor-
1 (PAI-1) should happen in the coagulation/fibrinoly-
sis system in the following stage. Since it is the prin-
cipal inhibitor of t-PA, it prevents the formation of
plasmin. The gap between the release of t-PA and the
increase in PAI-1 in the hypoperfusion status is con-
sidered to be several hours [26]. Thus, the phase of
the fibrinolytic shutdown follows soon after the DIC
phase with the fibrinolytic phenotype. Therefore, anti-
fibrinolytic agents used in the later phase of trauma
may not be beneficial and may even be harmful.
Pharmacological mechanisms of TXA
TXA is a synthetic derivative of the amino acid lysine that
inhibits fibrinolysis [27]. Plasma plasminogen is activated
and converted to plasmin by t-PA in the presence of fibrin.
Plasmin mainly degrades fibrin into fibrin/fibrinogen
degradation products. The degradation process requires
the connection of the lysine binding sites of plasminogen
with the lysine residues on the surface of fibrin. Since
TXA has a high affinity for the lysine binding sites of
plasminogen, it blocks the interaction of plasminogen with
the lysine residues of fibrin and exhibits an antifibrinolytic
effect [27].
Because the development of DIC associated with
the fibrinolytic phenotype may increase the mortality
in trauma, TXA is potentially beneficial to patients
who have developed hemostatic abnormalities during
the early phase of trauma. On the other hand, a de-
layed increase in PAI-1 results in the inhibition of
fibrinolysis in the later phase [28, 29]. Administration
of TXA could accelerate this change and develop det-
rimental effects when it is used during the fibrinolytic
shutdown phase. In fact, numerous basic research studies
have demonstrated the pro-thrombotic state enhanced by
TXA administration [30–33]. That is, the estimation of
the coagulation/fibrinolysis status is quite important to
gain the greatest benefit from TXA administration in
patients with trauma.
CRASH-2 trial
The CRASH-2 trial was a large randomized placebo-
controlled trial that evaluated the efficacy of TXA in pa-
tients with trauma [14]. It included 20,211 patients from
274 hospitals in 40 countries. Adult trauma patients who
were within 8 h of injury, with significant hemorrhaging
or considered to be at risk of significant hemorrhaging,
were eligible for the trial. Significant hemorrhaging was
defined as a systolic blood pressure of <90 mmHg or
heart rate >110 beats per min, or both. The patients
were randomly allocated to receive TXA or a placebo
(0.9% saline). TXA was infused 1 g over 10 min as a load-
ing dose, followed by another 1 g over 8 h. The primary
outcome was death in hospital within 4 weeks of injury,
and the cause of death was categorized into bleeding,
vascular occlusions, multiorgan failure, head injury, and
others. The secondary outcomes included vascular occlu-
sive events (myocardial infarctions, strokes, pulmonary
embolisms (PEs), and deep vein thromboses (DVTs)), re-
ceiving blood transfusions, and a transfusion of units of
blood products.
The primary outcome data were available for 20,127
patients, 10,060 of whom were allocated to TXA and
10,067 whom were allocated to a placebo. All-cause
mortality was significantly lower in the TXA group than
placebo group (14.5 vs. 16.0%), and death due to bleed-
ing was also significantly reduced by TXA (4.9 vs. 5.7%).
The secondary endpoints including a requirement for
surgery, receipt of blood transfusions, and transfusions
of units of blood products were equivalent between the
two groups. There were no significant differences between
the two groups in the occurrence of vascular occlusive
events (1.7 vs. 2.0%).
As the expected mechanism of TXA in trauma patients
with significant hemorrhaging was the inhibition of fibrin-
olysis leading to an improved hemostasis, an exploratory
analysis that examined the effect of TXA on death due to
bleeding according to the time to treatment was published
in Lancet [34]. Consequently, the risk of death due to
bleeding was reduced in two subgroups that received
treatment (TXA or placebo) in 1 h or less and between 1
and 3 h from the injury (5.3 vs. 7.7% and 4.8 vs. 6.1%, re-
spectively). On the other hand, TXA increased the risk of
death due to bleeding in a subgroup that received
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treatment more than 3 h after the injury (4.4 vs. 3.1%). It
proved that the sooner TXA is infused, the larger the im-
pact it has on death due to bleeding in trauma patients
with or at risk of significant hemorrhaging. Moreover, the
administration of TXA after 3 h from the injury may be
harmful. These results are reasonable because the mech-
anism of hemostatic abnormalities in trauma is known to
change dynamically from DIC with the fibrinolytic pheno-
type in the early phase into fibrinolytic shutdown with ele-
vated PAI-1 levels in the later phase.
Cochrane systematic review
A systematic review titled “Antifibrinolytic drugs for acute
traumatic injury” was updated in 2015 in the Cochrane
Database Syst Rev. [35]. Three trials were included in the
review, two trials assessed the effect of TXA, and the
other assessed that of aprotinin. Since the CRASH-2 trial
accounted for more than 99% of the study population, the
results from a pooled analysis were predominantly based
on the trial. The primary outcome was set as the mortality
at the end of the follow-up. Antifibrinolytic drugs reduced
the risk of death from any cause (relative risk (RR) 0.90,
95% confidence interval (CI) 0.85 to 0.96). There were no
significant differences in the secondary outcomes in-
cluding surgical intervention, blood transfusions, and
the volume of blood transfused. The adverse effects of
antifibrinolytic drugs such as PEs, DVTs, myocardial in-
farctions, and strokes were also evaluated, and it was
concluded that there was no evidence that antifibrinoly-
tic drugs had a detrimental effect on the risk of vascu-
lar occlusive events.
Recommendations in the related guidelines
Several guidelines have referred to TXA after the publi-
cation of the results of the CRASH-2 trial (Table 1). All
of them have recommended an early administration of
TXA in trauma patients.
The guidance for the diagnosis and treatment of DIC
by the International Society on Thrombosis and Haemo-
stasis (ISTH) has evaluated that the CRASH-2 trial has
provided a moderate quality of evidence [15]. The ISTH
guidance recommends the administration of TXA in the
early period of management, and to put it concretely, be-
fore the levels of PAI-1 and other endogenous antifibrinoly-
tics are elevated. A practical guideline for the hematological
management of major hemorrhage by the British Commit-
tee for Standards in Haematology also recommends the ad-
ministration of TXA in adult trauma patients with, or at
risk of, major hemorrhaging as soon as possible after an in-
jury (GRADE 1A) [36].
The STOP the Bleeding Campaign established by
several societies related to emergency medicine, sur-
gery, anesthesiology, hematology, and intensive care
medicine in Europe has published the guidelines on
the management of major bleeding and coagulopathy
following trauma [16]. It recommends the administra-
tion of TXA to trauma patients who are bleeding or at
risk of significant hemorrhaging as early as possible
(GRADE 1A) and to bleeding trauma patients within
3 h after an injury (GRADE 1B). On the other hand, it
recommends that TXA not be given after more than
3 h following an injury. It also refers to the administra-
tion of TXA en route to the hospital (GRADE 2C).
Similarly, a guideline for the assessment and initial
Table 1 Recommendations in the related guidelines
Guidelines Year Committee Recommendation
Guidance for diagnosis and treatment
of DIC from harmonization of the
recommendations from three
guidelines.
2013 The Scientific Standardization
Committee on DIC of the
International Society on
Thrombosis Haemostasis
Trauma patients who present with severe bleeding,
characterized by a marked hyperfibrinolytic state
could be treated with antifibrinolytic agents
(moderate quality).
A practical guideline for the
hematological management of
major haemorrhage.
2015 British Committee for
Standards in Haematology
Adult trauma patients with, or at risk of, major
hemorrhage, should be given TXA as soon as
possible after injury (grade 1A).
The European guideline on





for Advanced Bleeding Care
in Trauma
TXA administration was recommended as early
as possible to a trauma patient who is bleeding or
at risk of significant hemorrhaging (grade 1A)
Consider administration of the first dose of TXA
en route to the hospital (grade 2C)
Major trauma: assessment and
initial management.
2016 National Clinical Guideline
Centre
Use intravenous TXA as soon as possible in
patients with major trauma and active or
suspected active bleeding.
Do not use intravenous TXA more than 3 h
after injury in patients with major trauma unless
there is evidence of hyperfibrinolysis.
DIC disseminated intravascular coagulation, TXA tranexamic acid
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management of major trauma by the National Clinical
Guideline Centre recommends the usage of TXA as
soon as possible in patients with major trauma and ac-
tive or suspected active bleeding [37]. It also recom-
mends that TXA should not be infused when more
than 3 h has passed after an injury unless there is evi-
dence of hyperfibrinolysis.
Brief summary
Taken together, all the guidelines above demonstrate
the positive recommendation for TXA administration
after the CRASH-2 trial in a greater or lesser de-
gree. Now, can we really use TXA for all trauma
patients with significant hemorrhaging? Or should
we restrict the use of TXA to a limited specific
subset of trauma patients? Ian Roberts, one of the
authors of the CRASH-2 trial, argued that TXA
should be used in all trauma patients at risk of
bleeding in a review article in the J Intensive Care
[38]. Certainly, there is strong evidence that TXA
reduces the mortality in bleeding trauma patients,
as mentioned above. However, there is still concern
about the potential adverse events [14, 18, 39]. We
believe that the decision on the utilization of TXA ther-
apy depends on the balance between the efficacy and
safety of the therapy.
In the CRASH-2 trial, the rate of vascular occlusive
events did not differ significantly between the TXA
group and placebo group (TXA 1.7 vs. placebo 2.0%);
however, several papers have pointed out the limita-
tions of the results, such as the extremely low rate of
venous thromboembolisms (VTEs) reported in the
trial [17, 40, 41]. Furthermore, the authors of the
CRASH-2 trial admitted that the frequency of vascu-
lar occlusive events in the trial could be under-
reported [14]. Generally, for the assessment of the
safety of the treatment, it is surely acceptable to apply
the results of observational studies as well as random-
ized controlled studies (RCTs). Thus, we next tried to
briefly summarize the evidence for the safety of TXA
therapy by a systematic review method using both
RCTs and observational studies.
Methods of the systematic review
We conducted a systematic review to evaluate the TXA
therapy-related adverse events, especially thrombotic events
(VTEs). We searched MEDLINE (source, PubMed) up to
July 2016, for articles pertaining to TXA in patients with
trauma. We selected clinical trials that met the following
characteristics
1. Types of studies: RCTs and observational studies.
2. Types of participants: adult patients following an
acute traumatic injury. We excluded studies for only
patients with congenital, acquired bleeding disorders,
or planned surgical operations.
3. Intervention: intravenous administration of TXA.
4. Control: placebo or no antifibrinolytic drugs
5. Types of outcome measures: VTEs including PEs
and DVTs
Effect of TXA therapy on VTEs
We identified eight studies that evaluated the risk of VTEs
related to TXA in trauma patients (20,365 patients/two
RCTs and 2752 patients/six observational studies) [14, 19,
38, 41–45] (Table 2). The pooled relative risks for VTEs
were 0.84 (95% CI, 0.68–1.02) in the RCTs and 1.61
(95% CI, 0.86–3.01) in the observational studies (Fig. 1).
The pooled result of the RCTs was derived from only
the CRASH-2 trial. Here, we focused on the results of
the observational studies, which indicated a non-
significant increase in the VTE risk by TXA therapy. A
significant heterogeneity was observed (I2 = 52%), and
the point estimate of each study varied. Two of the six
studies showed a significant increased risk of VTEs by
TXA therapy, and three studies showed a non-
significant increased risk of VTEs.
These results suggested that TXA therapy may in-
crease the risk of thrombotic adverse events, but we ac-
knowledged several limitations in this quick review. The
risk of bias in the individual studies was serious because
of the observational study nature and pooled unadjusted
data. Most of the observational studies did not describe
the details of the diagnosis protocols or prophylactic
treatments for VTEs. Also, a serious imprecision of the
pooled estimated risk of VTEs was considered. So, the
quality of evidence about the VTE risk of the TXA ther-
apy was very low, and further research is likely to change
that estimate.
Does TXA not increase the VTE rate in the population at
high risk of VTEs?
Unlike our quick systematic review shown above,
Haren et al. reported that TXA was associated with
an improved fibrinolysis but did not increase the VTE
rate (TXA 33% vs. no TXA 27%) [43]. The targeted
population in this study was ICU trauma patients
with a high risk of VTEs defined as a Greenfield’s risk
assessment profile of ≥10. In the multivariate logistic
regression analysis adjusted for some confounders,
TXA was not significantly associated with VTEs. This
study was well-designed low risk of bias observational
study and easy to understand the main results. Taken
together with the conflicting results of our short sys-
tematic review, it is difficult to lead to a conclusion
as to whether TXA therapy is related to the risk of
thrombotic adverse events or not.
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Conclusions
As just described, TXA may have a survival benefit in
trauma patients with significant hemorrhaging. How-
ever, it is still controversial as to whether or not the
administration of TXA is associated with thrombo-
embolic complications. From the perspective of the
basic mechanism, TXA potentially possesses the risk
of VTEs, so we have to use it cautiously and select-
ively. Further investigation is needed to delineate the op-
timal targeted trauma patients to earn the maximum
survival benefit with the minimized risk of thrombotic
complications.
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